ImmVira’s oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA’s approval for Clinical Trial in China

SHENZHEN, China, March 30, 2023 /PRNewswire/ — ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration (“NMPA”) for Phase I clinical trial in China on March 29, 2023. Previously, MVR-C5252